Rationally designed viruses for use as vaccines or solid tumor therapies
Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.
Target customized oncolytics to treat primary tumors and shrink off-site metastases
177,000
RSV hospitalizations among adults 65+ no vaccine
48.8 million
Flu cases in 2017-18, current vaccines <37% effective
1 in 8
US women (about 12%) will develop invasive breast cancer during lifetime.
Our breakthrough approach to live-attenuated virus design
1. Recode
2. Synthesize
3. Transfect
4. Recover
-
January 15, 2020
Gates vets at Adjuvant back Codagenix’s software-driven approach to recoding RSV, flu, oncolytic viruses and more
Software is eating the way we make vaccines, and it has earned Farmingdale, NY-based biotech $20 million for a platform tech theoretically applicable to any virus — from influenza to oncolytic viruses targeted at cancer. Adjuvant Capital, the group of Gates Foundation veterans out to test a VC model for global health, led the Series […]
Full Story -
January 13, 2020
Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products
FOR IMMEDIATE RELEASE Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products Farmingdale, N.Y., January 13, 2020 – Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the closing of a $20 million Series B investment round. The new investment […]
Full Story